Company intelligence / Profile preview
Generex Biotechnology Corporation
Miramar, Florida, USAfacebook.com ↗
- Ownership
- Public · GNBT
- Development stage
- Phase 2
01
Overview
Generex developed several innovative technologies including an oral insulin spray (Oral‑lyn, approved in Ecuador), a HER2-targeting peptide vaccine (AE37, completed Phase IIb trials), wound healing products (Excellagen), point-of-care infectious disease diagnostics, and early-stage cell therapies. The company filed for Chapter 7 bankruptcy in April 2022 after years of financial difficulty. Asset sales were approved by court order in June 2022.
- Therapeutic areas
- GastroenterologyMetabolic DisordersRheumatologyImmunologyEndocrinologyDermatologyOtherOncologyInfectious Diseases
- Modalities
- Peptide vaccines (e.g., AE37)Oral insulin sprays (large molecule drugs)Cell therapy (Sertoli cells)Medical devices (wound care gels, surgical kits)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Fertin Pharma A/S – development of metformin medicinal chewing gum
04
Financials
- Market cap
- $0
- Total revenue
- $20.7K
- Enterprise value
- $7.6M
Beyond the preview
Go deeper on Generex Biotechnology Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Generex Biotechnology Corporation.